Amicus Therapeutics, Inc.

Equities

FOLD

US03152W1099

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 10:44:36 2024-05-23 am EDT 5-day change 1st Jan Change
9.535 USD -1.90% Intraday chart for Amicus Therapeutics, Inc. +0.26% -32.88%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Amicus Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 01:40 PM
Guggenheim Upgrades Amicus Therapeutics to Buy From Neutral With $13 Price Target MT
UBS Trims Price Target on Amicus Therapeutics to $19 From $20, Keeps Buy Rating MT
Amicus Therapeutics' Q1 Net Loss Narrows, Net Product Sales Rise MT
Transcript : Amicus Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024
Amicus Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Amicus Therapeutics, Inc. Provides Earnings Guidance for the Year 2024 CI
JPMorgan Adjusts Price Target on Amicus Therapeutics to $19 From $21, Maintains Overweight Rating MT
Amicus Therapeutics Insider Sold Shares Worth $389,543, According to a Recent SEC Filing MT
Transcript : Amicus Therapeutics, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Amicus Therapeutics Swings to Q4 Earnings, Revenue Rises MT
Earnings Flash (FOLD) AMICUS THERAPEUTICS Posts Q4 EPS $0.01, vs. Street Est of $-0.04 MT
Amicus Therapeutics, Inc. Provides Earnings Guidance for the Year 2024 CI
Amicus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Amicus Therapeutics Insider Sold Shares Worth $390,018, According to a Recent SEC Filing MT
Amicus Therapeutics Insider Sold Shares Worth $683,958, According to a Recent SEC Filing MT
Amicus Therapeutics Insider Sold Shares Worth $404,106, According to a Recent SEC Filing MT
Amicus Therapeutics Insider Sold Shares Worth $934,659, According to a Recent SEC Filing MT
Amicus Therapeutics Insider Sold Shares Worth $449,545, According to a Recent SEC Filing MT
Transcript : Amicus Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 02:15 PM
Amicus Therapeutics Sees Revenue Growth of 21% in 2023 MT
Amicus Therapeutics, Inc. Announces Unaudited Preliminary Revenue Results for the Fourth Quarter and Full Year of 2023 CI
Amicus Therapeutics, Inc. Provides Revenue Guidance for the Year 2024 CI
Amicus Therapeutics Insider Sold Shares Worth $734,007, According to a Recent SEC Filing MT
Amicus Therapeutics Insider Sold Shares Worth $490,411, According to a Recent SEC Filing MT
Chart Amicus Therapeutics, Inc.
More charts
Amicus Therapeutics, Inc. is a biotechnology company, which is focused on discovering, developing, and delivering novel medicines for rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a novel treatment designed to improve uptake of active enzyme into key disease relevant tissues for adults living with late-onset Pompe disease. As an orally administered monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A (alpha-Gal A) enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice (GLP) cell-based amenability assay. Pombiliti + Opfolda consists of a uniquely engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with miglustat that functions as an enzyme stabilizer.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
9.72 USD
Average target price
17.3 USD
Spread / Average Target
+77.98%
Consensus
  1. Stock Market
  2. Equities
  3. FOLD Stock
  4. News Amicus Therapeutics, Inc.
  5. Morgan Stanley Upgrades Amicus Therapeutics to Overweight From Equalweight, Raises Price Target to $20 From $15